Edition:
United States

Corvus Pharmaceuticals Inc (CRVS.OQ)

CRVS.OQ on NASDAQ Stock Exchange Global Market

9.87USD
10:17am EST
Change (% chg)

$-0.37 (-3.61%)
Prev Close
$10.24
Open
$10.10
Day's High
$10.10
Day's Low
$9.80
Volume
38,346
Avg. Vol
18,919
52-wk High
$22.01
52-wk Low
$8.27

Latest Key Developments (Source: Significant Developments)

Corvus Pharmaceuticals reports third quarter 2017 financial results
Thursday, 2 Nov 2017 04:10pm EDT 

Nov 2 (Reuters) - Corvus Pharmaceuticals Inc ::Corvus Pharmaceuticals reports third quarter 2017 financial results and clinical program update.Net loss for three months ended September 30, 2017, was $12.7 million compared to $10.3 million for same period in 2016​.  Full Article

Corvus Pharmaceuticals qtrly ‍net loss per share $0.73​
Thursday, 3 Aug 2017 04:10pm EDT 

Aug 3 (Reuters) - Corvus Pharmaceuticals Inc :Corvus Pharmaceuticals reports second quarter 2017 financial results and provides business update.Corvus Pharmaceuticals Inc - qtrly ‍ net loss per share, basic and diluted $0.73​.Q2 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S.  Full Article

Corvus Pharmaceuticals announces interim results from its ongoing Phase 1/1b study
Monday, 5 Jun 2017 08:30am EDT 

June 5 (Reuters) - Corvus Pharmaceuticals Inc ::Announces interim results demonstrating anti-tumor activity of CPI-444 in renal and lung cancer patients resistant or refractory to prior PD-(L)1 treatment.Criteria met for second expansion of renal cell cancer cohort treated with combination therapy​.  Full Article

Corvus Pharmaceuticals and Monash University enter into exclusive license agreement
Tuesday, 9 May 2017 08:30am EDT 

May 9 (Reuters) - Corvus Pharmaceuticals Inc ::Corvus Pharmaceuticals and Monash University enter into exclusive license agreement for novel immuno-oncology program.Corvus Pharmaceuticals - licensed global rights to undisclosed novel immuno-oncology program, which includes lead product candidate, from Monash University.  Full Article

Corvus Pharma Q1 loss per share $0.79
Thursday, 4 May 2017 04:10pm EDT 

May 4 (Reuters) - Corvus Pharmaceuticals Inc ::Corvus Pharmaceuticals reports first quarter 2017 financial results and provides business update.Qtrly loss per share $0.79.  Full Article

Corvus Pharmaceuticals expands CPI-444 clinical collaboration with Genentech
Tuesday, 2 May 2017 08:30am EDT 

May 2 (Reuters) - Corvus Pharmaceuticals Inc : :Corvus Pharmaceuticals expands cpi-444 clinical collaboration with Genentech.Corvus Pharmaceuticals - Genentech will manage study operations for phase 1B/2 trial, which is expected to begin enrolling patients in second half of 2017.Corvus Pharmaceuticals Inc - financial terms were not disclosed.Corvus Pharmaceuticals Inc - Corvus will retain global development and commercialization rights to CPI-444.Corvus Pharmaceuticals Inc- expanded its clinical collaboration with Genentech, a member of Roche Group.Corvus Pharmaceuticals Inc- anticipated that randomized, controlled study will enroll up to 65 patients in treatment arm.  Full Article

Corvus Pharmaceuticals announces interim safety and efficacy results from its ongoing Phase 1/1B study of CPI-444
Tuesday, 4 Apr 2017 10:30am EDT 

Corvus Pharmaceuticals Inc : Corvus Pharmaceuticals announces interim results from ongoing Phase 1/1B study demonstrating safety and clinical activity of lead checkpoint inhibitor CPI-444 in patients with advanced cancers . Trial data showed that treatment with CPI-444 as a single agent and in combination with atezolizumab was well tolerated . Says CPI-444 has been well tolerated to date .Of 37 patients who showed evidence of disease control, 23 remain on treatment.  Full Article

Corvus Pharmaceuticals files for mixed shelf of upto $250 mln
Monday, 3 Apr 2017 07:00am EDT 

Corvus Pharmaceuticals Inc : Corvus Pharmaceuticals Inc - files for mixed shelf of upto $250 million - SEC filing Source: (http://bit.ly/2osIJ7a) Further company coverage: [CRVS.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Corvus Pharmaceuticals qtrly loss per share $0.55
Friday, 10 Mar 2017 08:00am EST 

Corvus Pharmaceuticals Inc : Corvus Pharmaceuticals reports fourth quarter and full year 2016 financial results and provides business update . Corvus Pharmaceuticals inc qtrly loss per share $0.55 . Corvus Pharmaceuticals inc - sees net cash utilization of $55 million to $60 million in 2017 .Corvus Pharmaceuticals inc - at December 31, 2016, corvus had cash, cash equivalents and marketable securities totaling $134.9 million.  Full Article

Corvus Pharmaceuticals announces expansion of renal cell carcinoma cohort in ongoing clinical study of lead checkpoint inhibitor CPI-444
Tuesday, 10 Jan 2017 08:30am EST 

Corvus Pharmaceuticals Inc : Corvus Pharmaceuticals announces expansion of renal cell carcinoma cohort in ongoing phase 1/1b clinical study of lead checkpoint inhibitor CPI-444 . Cohort reached protocol-predefined criteria for expansion based on responses to single-agent treatment . Could potentially initiate a registration trial before end of 2017 .To date, CPI-444 has been well tolerated when given orally twice daily..  Full Article

BRIEF-Corvus Pharmaceuticals reports third quarter 2017 financial results

* Corvus Pharmaceuticals reports third quarter 2017 financial results and clinical program update